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Arachidonic acid (AA) and docosahexaenoic acid (DHA) are important long-chain polyun-
saturated fatty acids for neuronal and cognitive development and are ingredients of infant
formulae that are recommended but there is no evidence based minimal supplementation
level available. The aim of this analysis was to investigate the effect of supplemented AA
and DHA on phospholipid metabolism.
Methods
Plasma samples of a randomized, double-blind infant feeding trial were used for the analy-
ses of phospholipid species by flow-injection mass spectrometry. Healthy term infants con-
sumed isoenergetic formulae (intervention formula with equal amounts of AA and DHA—IF,
control formula without additional AA and DHA—CF) from the first month of life until the age
of 120 days. A group of breast milk (BM) -fed infants was followed as a reference.
Results
The plasma profile detected in newborns was different from 4 month old infants, irrespective
of study group. Most relevant changes were seen in higher level of LPC16:1, LPC20:4,
PC32:1, PC34:1 and PC36:4 and lower level of LPC18:0, LPC18:2, PC32:2, PC36:2 and
several ether-linked phosphatidylcholines in newborns. The sum of all AA and DHA species
at 4 month old infants in the CF group showed level of 40% (AA) and 51% (DHA) of new-
borns. The supplemented amount of DHA resulted in phospholipid level comparable to BM
infants, but AA phospholipids were lower than in BM infants. Interestingly, relative contribu-
tion of DHA was higher in ether-linked phosphatidylcholines in CF fed infants, but IF and
BM fed infants showed higher overall ether-linked phosphatidylcholines levels.
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Conclusion
In conclusion, we have shown that infant plasma phospholipid profile changes remarkably
from newborn over time and is dependent on the dietary fatty acid composition. A supple-
mentation of an infant formula with AA and DHA resulted in increased related phospholipid
species.
Introduction
After birth, breast milk consumption is assumed to be the best nutrition to support optimal
infantile development. Thus, infant formulae should be designed according to human milk
composition to meet infant’s needs. Besides protein and carbohydrate content, lipid composi-
tion is essential, e.g. an essential fatty acid ratio of linoleic acid to alpha-linolenic acid ratio in
the range of 5–15 is recommended [1, 2]. Arachidonic acid (AA) and docosahexaenoic acid
(DHA) are the most important essential long-chain polyunsaturated fatty acids (LC-PUFA)
which are recommended ingredients for infant formula, but there are no evidence based mini-
mal supplementation level available. A series of studies have shown that LC-PUFA supplemen-
tation of infant formula improved the fatty acids status in different matrices such as plasma
and red blood cells in infants [3]. Phospholipids are membrane lipids and known to be a good
biomarker for LC-PUFA status, due to a high content of these essential fatty acids [4]. Thus,
the analysis of plasma phospholipids is used to assess the bioavailability of supplemented
LC-PUFA. For the development of new infant formulae, fatty acid analyses of plasma or red
blood cell phospholipids are usually used to determine the fatty acid status [5].
Phospholipids are molecules with a lipophilic fatty acid side chain and a hydrophilic phos-
phate containing head group. Hundreds of diverse molecular species of phospholipids that dif-
fer in kind of head group, chain length, number and positions of double bonds and chemical
bindings of fatty acids to the glycerol or sphingosine backbone [6] are known. There are several
lipid molecules that contain fatty acid chains like AA or DHA. Thus, it seems to be important
to know how supplemented LC-PUFA is incorporated in the lipidome and which metabolites
reflect LC-PUFA best in infant plasma.
To investigate this question, we chose a previously published randomized, double-blind
intervention trial which investigated a new designed low protein intervention formula (IF) sup-
plemented with equal amounts of AA and DHA (7.2 mg/ 100 mL) in comparison to a control
formula (CF) without AA and DHA [7]. Fully breastfed infants were followed as a non-ran-
domized reference group. The supplemented AA and DHA in the IF resulted in higher per-
centages of these fatty acids in plasma glycerophospholipids in comparison to CF [7]. The aim
of this analysis was to investigate the effect of supplemented AA and DHA and the change of
different plasma phospholipid species in the first month of life. We focused our analysis on
choline containing phospholipid species, namely lyso-phosphatidylcholines (LPC), diacyl-
phosphatidylcholines (PC), ether-linked phosphatidylcholines (PCe) and sphingomyelines
(SM), which covered 95% of phospholipids [8].
Methods
Study
We analysed plasma samples of infants from the BeMIM study (Belgrade-Munich Infant Milk
trial), a randomized, double-blind, controlled intervention study. Details on the study design,
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participating subjects, as well as details about infant formula composition have been previously
published [7]. Briefly, healthy term infants were recruited until the age of 28 days and rando-
mised to receive either an intervention formula (IF) with AA and DHA (from egg and fish oils)
or a control formula (CF) without AA and DHA. Furthermore, IF had a lower protein content
(1.89 g/100 kcal) and a higher fat content (5.3 g/ 100 kcal), compared to the CF (2.2 g protein
and 4.9 g fat per 100 kcal). IF was enriched in alpha-lactalbumin and supplemented with free
L-phenylalanine and L-tryptophan to meet required contents [2]. A reference group of exclu-
sively breastfed infants was included (BM). Plasma samples were taken at 120 days of age and
from a subgroup of subjects plasma samples were taken at recruitment before the study started
(newborn, 0–5 days after birth). Newborn and subjects did not fully coincide after the interven-
tion due to drop outs and thus a longitudinal analysis was unrewarding. The study was
approved by the Clinical Center Serbia Ethical Committee. Written informed consent was
obtained from all participating families. Analyses of this publication have been performed as
secondary analyses of a randomized controlled trial and got approval from the Ethical Com-
mittee of Ludwig-Maximilians University of Munich, Germany. The original study was regis-
tered at Clinical Trials.gov (NCT01094080). The fatty acid compositions of both infant
formulas are shown in Table 1.
Analysis of glycerophospholipids
The plasma samples were analysed as described in S1 File and in previous studies [9–11].
Briefly, 10 μl plasma were diluted with methanol, containing internal standards, to correct for
any effects appearing during sample preparation and ionization. After centrifugation, superna-
tants were used for flow-injection mass spectrometry analysis. The liquid chromatographic sys-
tem (Agilent, Waldbronn, Germany) was coupled to a triple quadrupole mass spectrometer
(QTRAP4000, Sciex, Darmstadt, Germany) with an electrospray ionization source. Mass spec-
trometric analysis was run in Multiple Reaction Monitoring mode. Quantification of metabo-
lites has been done by comparison of signal-to-internal standard-ratios between samples and
commercial available lyophilized aliquots of control plasma (Recipe, Germany) as one point
calibration. The entire analytical process was post-processed by Analyst 1.5.1 and the isotopo-
mer correction for up to M+4 was applied by R (programming language, version 3.0.1).
The full analytical analysis comprised LPC, PC, PCe, SM, acylcarnitines and sum of hexoses,
but data analyses focus only on phospholipids. As a point to note, the analytical technique
applied here is not capable of determining the position of the double bonds and the distribution
of carbon atoms between fatty acid side chains. The polar lipids are mentioned as X:Y. In this
Table 1. Fatty acid content (g/100mL) of the studied infant formulas.









C20:4 (mg/100 mL) 7.2 0
C22:6 (mg/100 mL) 7.2 0
doi:10.1371/journal.pone.0162040.t001
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nomenclature, X is the length of the carbon chain, Y is the number of double bonds. There will
be no differentiation between ether-linked and vinyl ether-linked phosphatidylcholines. How-
ever in PC, the ether-linked species are dominating and thus the interpretation of fatty acids
follows this assumption. Furthermore, it needs to be addressed that there might be more than
one species covered by one mass transition and the most concentrated species (according to
lipidmaps.org [12] and human metabolome data base [13]) was used as species name.
Data analysis
A number of 484 plasma samples were measured randomly in batches composed of 81 sam-
ples, 6 quality control samples and 9 standards. Aliquots of a pooled plasma sample were used
as quality control samples for intra- and inter-batch variation. Coefficients of variation were
used as the criteria of quality. Metabolites are presented as median and interquartile ranges
(IQR) in μmol/L. A principal component analyses (PCA) was carried out to identify possible
separation of subjects according to grouping. Mann-Whitney-U tests were performed to inves-
tigate differences between groups. Significance was accepted at p<0.05. Due to multiple test-
ing, the level of significance for p-values was corrected according to Bonferroni to p-values
<5.49E-04. All statistical tests were performed with SPSS software version 21 (IBM, NY, USA)
or Excel 2010.
Results
A total of 484 plasma samples (231 newborn, 79 CF, 83 IF and 91 BM) of the BeMIM trial have
been determined for 425 phospholipids. Eleven LPC, 26 PC, 27 PCe and 27 SM were deter-
mined with intra-batch and inter-batch coefficient of variation less than 30% and considered
for further statistical analysis. Details on the anthropometric data have been previously pub-
lished [7]. Briefly, the mean age of the 231 newborn was 3 days (range 2 to 5) with a mean
birthweight of 3437 g (SD 373 g).
Changes from birth to 4 month of age
The plasma profile of newborn was strictly different from the plasma profile of 4 month old
infants, irrespective of study group as illustrated in the plot of principal component 1 and 2 of
the PCA analyses (Fig 1). The separation was found approximately along the angle bisector
and thus both principal components were responsible for the separation. Loadings of the prin-
cipal components did not identify a specific class of phospholipids, responsible for the separa-
tion. Mann-Whitney-U test identified 75 metabolites with different concentrations in the
newborn compared to BM infants at 4 month of age (Table 2). This corresponds to 82% of all
detected species. Most relevant different species were LPC16:1, LPC20:4, PC32:1, PC34:1 and
PC36:4 with higher concentrations and LPC18:0, LPC18:2, PC32:2, PC36:2 and several PCe
with lower concentrations in the newborn. The sum of all PCe species was rising from newborn
to 4 month old infants with median (IQR) values of 85 (32) μmol/L for newborn, 92 (22) μmol/
L for CF, 109 (24) μmol/L for IF and 127 (35) μmol/L for BM. PC36:4 was the highest phospho-
lipid species in newborn, while PC34:2 was highest at 4 month of age. Strong effects were seen
in species with AA and DHA, especially to the group of CF, which did not receive any addi-
tional AA and DHA over the study period. Nearly all species with these two fatty acids were
affected and thus the sum was calculated to assess the total effect (Fig 2). Highest values for AA
were found at the time of birth and all groups showed significant lower level at 4 month. Low-
est values for AA as well as for DHA species were detected in the CF group. The DHA content
at 4 month of age was not different between the IF and the BM group compared to the
newborn.
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Group comparison
To find out what effect supplemented AA and DHA on different plasma phospholipid species
might have at 4 month of age, a Mann-Whitney-U test between the two formula groups was
performed. A total of 51 species turned out to be significant different, which corresponds to
56% of detected metabolites (Table 2). Phospholipid species containing 6 double bonds pre-
sumably represent the presence of DHA, which are in detail LPC22:6, PC36:6, PC38:6, PC40:6,
PCe36:6, PCe38:6, PCe40:6, and PCe42:6. The concentrations of all 8 species were significant
lower in CF. In IF fed infants, all di-acylated PC species were between 2.25 and 2.37 fold higher.
PCe species were enriched between 1.34 and 1.75 fold. Phospholipids containing AA were pre-
sumably LPC20:4, PC34:4, PC36:4, PC38:4, PC40:4, PCe34:4, PCe36:4, PCe38:4, and PCe40:4.
All but PC40:4 and PCe40:4 were higher in the IF group.
To evaluate compositional shifts, the relative distribution of all DHA and AA containing
species was calculated, separately. In the CF, a higher compositional content of DHA was
found for the species PCe38:6, PCe40:6 and PCe42:6 and a lower content was found for
PC38:6. The composition of AA species was affected with higher values of PC34:4 and lower
values of PC40:4.
Fig 1. Principal component analyses of the phospholipid profile of newborn (n = 231) and at 4 month of
age fed an intervention formula (IF, n = 83), a control formula (CF, n = 79) or breast milk (BM, n = 91).
doi:10.1371/journal.pone.0162040.g001
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Table 2. Median (M) and interquartile ranges (IQR) of plasma lipids (in μmol/L) of newborn (NB, n = 231) and at 4 month of age fed an intervention
formula (IF, n = 83), a control formula (CF, n = 79) or breast milk (BM, n = 91). Mann-Whitney-U tests with Bonferroni correction were performed to com-
pare between the groups. Significant (Sig.) changes (p <0.05) are marked in gray.
Metabolite NB CF IF BM NB vs BM CF vs IF IF vs BM
M IQR M IQR M IQR M IQR
LPC14:0 0.87 0.36 0.56 0.35 0.90 0.41 1.12 0.46 1.10E-11 3.67E-10 1.68E-05
LPC16:0 89.24 26.88 69.18 10.62 72.01 13.96 70.11 13.23 2.71E-14 3.43E-02 5.83E-02
LPC16:1 3.32 1.26 1.23 0.29 1.26 0.45 1.58 0.54 7.67E-38 9.67E-01 2.68E-07
LPC18:0 21.52 6.47 23.78 5.04 26.51 6.18 28.82 7.31 6.25E-27 2.37E-05 5.15E-04
LPC18:1 22.84 8.09 20.26 4.66 19.65 4.38 18.79 6.35 5.15E-09 4.79E-02 6.59E-01
LPC18:2 21.32 10.93 41.57 8.54 44.14 16.21 44.31 12.85 3.33E-33 1.01E-01 6.33E-01
LPC20:3 1.95 0.97 1.32 0.51 1.22 0.44 1.67 0.74 6.51E-04 1.49E-01 8.14E-10
LPC20:4 14.93 4.29 3.80 1.65 5.03 2.00 6.82 2.85 5.44E-38 4.47E-07 3.90E-12
LPC22:6 2.96 1.13 0.95 0.66 2.22 1.02 2.00 0.65 1.88E-22 8.31E-20 3.09E-02
LPCe16:0 0.24 0.13 0.26 0.16 0.29 0.15 0.47 0.22 6.88E-31 1.34E-01 1.22E-11
LPCe18:0 0.49 0.20 0.51 0.20 0.54 0.28 1.01 0.49 5.31E-35 1.01E-01 4.08E-14
PC30:0 3.16 1.38 1.32 0.78 2.26 0.72 3.02 1.25 2.33E-01 1.13E-10 1.04E-09
PC32:0 28.19 10.91 13.17 3.82 14.58 3.25 15.87 4.97 1.46E-33 4.96E-03 5.92E-03
PC32:1 24.49 12.26 7.14 2.05 7.36 2.72 8.69 3.36 4.27E-42 4.07E-01 3.01E-04
PC32:2 0.79 0.64 1.33 0.58 1.79 0.75 1.69 0.97 8.42E-28 8.34E-08 7.01E-01
PC34:1 249.96 121.42 188.03 44.08 182.17 44.89 149.28 39.94 5.63E-34 2.50E-01 1.31E-07
PC34:2 246.66 128.86 440.37 86.72 468.43 115.00 413.68 113.86 1.19E-22 1.65E-01 1.18E-04
PC34:3 4.70 2.66 7.55 2.24 8.93 2.44 6.77 2.47 6.45E-14 9.36E-06 1.04E-10
PC34:4 0.46 0.21 0.41 0.24 0.61 0.27 0.71 0.31 5.86E-17 1.02E-08 3.35E-03
PC34:5 0.08 0.06 0.06 0.04 0.11 0.06 0.08 0.05 3.63E-01 8.19E-08 9.48E-05
PC36:0 1.90 1.01 1.24 0.86 2.59 0.80 2.32 0.72 3.61E-05 3.01E-19 3.58E-04
PC36:1 40.54 18.94 42.50 9.20 43.85 11.02 41.40 11.92 9.12E-01 4.81E-01 5.83E-02
PC36:2 129.68 69.80 267.34 50.27 284.88 72.88 289.96 88.42 1.76E-36 5.90E-02 5.60E-01
PC36:3 75.49 38.56 107.04 23.38 95.96 26.04 107.78 37.21 1.82E-13 1.17E-03 2.40E-03
PC36:4 284.46 108.48 103.66 31.36 130.38 34.52 162.10 55.63 8.04E-34 6.93E-08 2.24E-07
PC36:5 4.89 2.64 3.74 1.86 6.03 2.49 4.71 1.48 1.37E-01 8.36E-15 4.27E-08
PC36:6 0.20 0.11 0.17 0.12 0.38 0.18 0.31 0.11 1.42E-16 3.33E-16 4.31E-05
PC38:1 0.64 0.62 0.94 0.54 1.33 0.53 1.39 0.44 1.51E-23 5.43E-08 4.95E-01
PC38:3 20.81 10.54 22.64 6.36 22.46 7.22 26.03 10.32 1.85E-08 1.96E-01 1.79E-09
PC38:4 170.97 61.08 69.42 28.41 89.31 24.20 136.35 52.48 2.73E-13 7.78E-07 3.58E-15
PC38:5 33.74 13.94 28.93 8.75 30.59 8.54 35.08 12.30 3.20E-01 1.23E-01 1.79E-05
PC38:6 74.86 32.02 35.39 25.96 83.73 34.15 68.30 22.33 2.97E-04 2.47E-20 2.69E-06
PC40:4 2.89 1.35 2.51 0.72 2.30 0.65 3.20 1.22 1.42E-03 7.76E-03 4.90E-15
PC40:5 6.89 3.57 7.01 2.08 7.21 2.38 8.46 3.16 5.60E-07 9.75E-01 1.13E-06
PC40:6 22.92 10.53 12.51 9.33 28.19 11.06 25.11 8.05 1.62E-02 5.52E-19 6.15E-02
PC42:5 0.23 0.11 0.26 0.12 0.27 0.11 0.35 0.12 7.63E-19 3.22E-01 1.14E-08
PC44:12 0.73 0.33 0.94 0.26 1.14 0.33 1.04 0.29 1.11E-15 3.65E-08 2.55E-03
PCe32:0 3.34 1.30 3.07 0.78 2.97 0.72 3.11 0.76 1.92E-02 8.32E-01 2.33E-01
PCe32:1 3.15 1.19 2.07 0.50 2.39 0.65 2.40 0.70 5.08E-16 1.38E-05 6.73E-01
PCe32:2 0.50 0.20 0.25 0.12 0.30 0.12 0.30 0.16 7.48E-20 3.35E-04 1.04E-01
PCe34:0 1.03 0.42 0.63 0.31 0.67 0.42 1.25 0.60 1.15E-03 3.81E-01 5.39E-14
PCe34:1 5.43 2.49 7.06 1.83 6.87 1.79 6.86 1.72 2.03E-08 5.06E-01 6.52E-01
PCe34:2 3.89 1.52 7.08 1.78 6.90 1.80 6.32 1.77 4.00E-27 2.14E-01 3.69E-02
PCe34:3 2.34 1.32 4.53 1.07 5.08 1.52 4.17 1.38 5.34E-28 4.08E-02 2.11E-03
PCe34:4 0.08 0.05 0.09 0.04 0.13 0.06 0.12 0.05 6.39E-09 2.32E-07 9.13E-04
(Continued)
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Table 2. (Continued)
Metabolite NB CF IF BM NB vs BM CF vs IF IF vs BM
M IQR M IQR M IQR M IQR
PCe36:0 0.71 0.30 0.53 0.20 0.60 0.16 0.65 0.22 2.21E-03 1.01E-03 1.46E-01
PCe36:1 1.64 0.73 1.76 0.59 1.93 0.71 2.87 1.16 9.72E-24 5.22E-02 5.03E-11
PCe36:2 2.86 1.37 6.26 1.57 6.56 1.66 8.90 4.09 3.90E-42 5.30E-02 5.35E-10
PCe36:3 1.88 0.78 4.64 1.22 4.40 1.24 4.51 1.29 1.48E-39 7.94E-02 6.61E-01
PCe36:4 12.50 4.97 10.09 2.72 11.72 3.01 13.59 4.41 1.74E-02 9.22E-06 2.03E-06
PCe36:5 10.01 4.39 6.61 2.26 8.99 2.57 11.24 3.14 2.93E-02 8.65E-11 2.90E-07
PCe36:6 0.08 0.13 0.11 0.16 0.19 0.14 0.19 0.13 1.40E-13 4.02E-06 9.12E-01
PCe38:0 0.73 0.37 0.52 0.35 1.07 0.44 1.06 0.44 1.78E-15 2.71E-19 6.90E-01
PCe38:4 9.43 3.38 7.42 2.23 8.75 2.45 13.60 6.24 7.46E-15 1.95E-05 1.69E-15
PCe38:5 9.82 4.04 13.63 3.98 16.25 3.43 20.14 6.28 5.68E-35 2.45E-07 6.93E-09
PCe38:6 4.52 1.94 3.71 1.98 6.40 1.36 7.09 1.56 1.82E-19 3.59E-17 4.51E-03
PCe40:0 2.93 1.29 2.39 1.31 4.10 1.27 3.88 1.18 1.00E-09 4.39E-16 3.06E-02
PCe40:1 0.90 0.33 0.67 0.38 1.22 0.40 1.14 0.39 4.12E-09 2.90E-16 1.02E-01
PCe40:4 1.39 0.57 1.22 0.37 1.33 0.40 1.84 0.74 1.82E-11 2.94E-03 3.03E-13
PCe40:5 1.70 0.63 2.17 0.77 2.57 0.83 3.53 1.23 1.50E-37 1.89E-05 4.83E-12
PCe40:6 1.95 0.73 2.19 1.03 3.58 0.75 4.15 1.32 1.94E-37 1.28E-15 4.53E-07
PCe42:2 0.18 0.11 0.21 0.10 0.25 0.09 0.26 0.08 7.90E-14 3.09E-05 7.69E-01
PCe42:5 0.68 0.31 0.87 0.35 1.09 0.29 1.17 0.41 2.56E-28 1.45E-07 3.67E-02
PCe42:6 0.70 0.29 0.73 0.32 0.98 0.27 1.10 0.38 7.20E-23 5.63E-10 1.25E-03
SM12:0 0.32 0.15 0.39 0.38 0.88 0.29 0.86 0.45 2.73E-37 2.13E-16 6.27E-01
SM14:0 6.87 2.48 15.82 4.80 15.23 3.08 14.86 4.36 1.03E-38 4.25E-01 6.81E-02
SM14:1 0.61 0.23 0.35 0.22 0.61 0.22 0.78 0.42 1.10E-11 5.36E-13 3.30E-07
SM15:0 3.83 1.60 5.85 1.56 5.68 1.26 5.95 1.44 3.96E-22 5.46E-02 1.75E-02
SM16:0 103.65 32.88 102.98 20.99 118.18 17.23 125.20 28.13 2.00E-08 1.04E-06 2.21E-02
SM16:1 17.21 5.52 11.47 2.59 12.70 2.23 14.61 4.04 6.21E-08 3.05E-05 7.94E-06
SM17:0 2.20 0.88 1.83 0.50 1.86 0.56 3.13 1.30 1.60E-13 8.78E-02 5.60E-16
SM18:0 33.43 11.19 21.16 5.56 24.28 5.03 27.88 8.52 1.02E-10 4.83E-04 1.10E-06
SM18:1 18.74 6.71 7.02 2.17 8.62 2.33 12.78 5.20 1.16E-25 7.92E-07 3.70E-13
SM18:2 0.55 0.26 0.48 0.18 0.60 0.23 1.07 0.56 7.32E-24 2.40E-05 1.85E-14
SM19:0 1.40 0.60 1.56 0.75 1.58 0.53 1.89 0.54 4.09E-13 2.70E-01 2.25E-04
SM20:0 22.49 9.77 33.96 10.91 34.92 9.33 30.67 9.99 1.98E-10 4.68E-01 1.14E-04
SM20:1 10.26 4.12 11.30 2.40 12.27 3.42 11.36 2.67 5.62E-02 9.00E-03 5.44E-03
SM21:0 1.75 0.75 5.52 2.01 4.95 1.36 4.27 1.58 1.86E-39 1.42E-02 6.24E-06
SM22:0 14.30 5.00 13.01 6.59 14.58 5.10 11.13 6.03 4.19E-11 1.38E-01 1.13E-06
SM22:1 17.68 7.51 25.20 6.47 28.00 6.51 26.01 6.62 3.65E-21 2.58E-02 1.81E-01
SM22:3 5.84 1.97 2.44 0.76 2.85 0.84 3.23 0.93 4.17E-33 1.23E-07 1.24E-02
SM22:4 0.43 0.18 0.24 0.10 0.36 0.15 0.36 0.12 1.45E-05 5.63E-10 4.41E-01
SM23:0 3.57 1.76 6.91 1.88 6.93 1.53 6.48 1.84 3.46E-30 4.40E-01 2.16E-02
SM24:0 14.78 5.14 10.65 2.55 12.22 2.29 12.00 3.59 1.18E-10 2.88E-06 4.97E-01
SM24:1 35.04 12.74 29.50 8.33 37.82 7.29 35.11 8.96 8.47E-01 1.48E-11 1.86E-01
SM24:2 22.31 8.13 14.63 4.33 17.10 3.85 21.45 7.84 3.49E-02 6.67E-08 3.60E-08
SM24:3 11.96 4.13 5.10 1.95 6.17 1.99 9.71 4.55 2.44E-11 5.92E-05 1.82E-15
SM24:5 3.95 1.55 1.82 1.41 4.06 1.48 3.38 1.16 1.16E-06 3.27E-20 6.93E-05
SM25:1 0.87 0.43 0.54 0.24 0.70 0.26 1.15 0.60 8.53E-08 3.03E-07 7.86E-13
SM13:0 0.13 0.06 0.13 0.08 0.16 0.09 0.23 0.13 7.62E-24 1.86E-05 7.81E-07
SM17:1 0.31 0.15 0.20 0.10 0.23 0.10 0.46 0.22 3.27E-12 1.62E-02 2.17E-16
doi:10.1371/journal.pone.0162040.t002
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Discussion
The phospholipid profile of infants a few days after birth was quite different to the phospho-
lipid profiles at 4 months of age, irrespective of the study group. We found remarkable high
concentrations of LPC(20:4) and PC(36:4) in newborn. PC(36:4) is composed to the main
extend of PC(16:0/20:4) [14], which represents the phospholipid species with the highest con-
tent of AA. AA is known to be preferably transported through the placenta, but the process of
transport is not jet completely understood [15]. In a previous study we found a high correlation
of cord blood AA to placental PC(16:0/20:4) content and we speculated that placental PC(16:0/
20:4) might be the source of AA for the fetal development and that this molecule plays a major
role in the transport mechanism [16]. In the current study we could now specify the AA con-
tent in the newborn metabolism to 9 different AA containing species with a high proportion in
the molecular species of PC(16:0/20:4). Furthermore, the high concentration of PC(36:4) in
newborn might fit to the theory that fatty acids are released as free fatty acids from the placenta
to the fetal circulation and then are further metabolised to phospholipids to be protect from
the placental reabsorption [17]. Our finding of high LPC(20:4) concentration are not easy
understandable, since lyso-phospholipids are thought to be produced from phospholipases A1
or A2. In phospholipids the AA is located at the sn-2 position and thus a phospholipase A1
would be necessary to produce LPC(20:4), albeit the phospholipases A1 is rarely distributed.
Fig 2. Sum of all species containing docosahexaenoic acid (black bar) and arachidonic acid (white bars) in newborn (n = 231) and at 4
month feeding a control formula (CF, n = 79), intervention formula (IF, n = 83) or breast milk (BM, n = 91). Significant differences to newborn
are marked with an asterisk.
doi:10.1371/journal.pone.0162040.g002
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Thus, it seems to be unrealistic that a phospholipase is responsible for the LPC(20:4). A further
possible candidate might be the lecithin-acyl-transferase (LCAT), which transfers a fatty acid
from phospholipids to cholesterol and releases a lyso-phospholipid. The sn-1 activity of LCAT
was found to be dependent on the fatty acid chain length of the fatty acid on position sn-1 with
50% sn-1 activity for PC(16:0/20:4) [18]. Thus, this might be a good candidate for LPC(20:4)
source. However, a new developed transporter for lyso-phospholipids was discussed to be
responsible for the transport of LPC(22:6) through the placenta [19]. One could speculate
about this process being also responsible for the transport of AA to the fetal metabolism.
In case of no further nutritional supply of LC-PUFA, their concentration decrease after
birth and remain constant at lower level after a period of less than 3 months as shown in a
study on the 13C-content of plasma fatty acids over time [20]. At the age of 4 months, the lower
concentrations of phospholipid species with AA or DHA represents the endogenous synthesis
of AA and DHA from linoleic acid (18:2n-6) and alpha-linolenic acid (18:3n-3) of CF feeding
without additional AA and DHA supply, respectively [21]. The comparison between CF and
newborn allowed assessing roughly the contribution of placental transfer to AA and DHA con-
tent in comparison to endogenous production. Fig 2 shows the level of all AA and DHA species
in newborn and CF. In CF, level were significant lower with values of 40% AA and 51% DHA
at 4 month of age compared to newborn. Thus, we conclude that the contribution of placental
transfer during pregnancy of AA and DHAmust be more than 50%. During pregnancy, the
placental contribution is presumably even higher, since the endogenous production is not fully
developed.
Breast milk is very complex and can show very high variation in the content. Thus, effects
can always be multifactorial and causal changes might be difficult. In vivo studies of AA and
DHA can be affected by their precursors such as dihomo-γ-linolenic acid and eicosapentaenoic
acid. In this study, the two formula groups have the same fatty acid composition up to addi-
tional AA and DHA in the intervention group and effects can be limited to these fatty acids.
The comparison between the IF and CF group allowed to assess the effect of dietary LC-PUFA
to the endogenously produced LC-PUFA in very similar feeding groups. In IF group, all AA
and DHA containing species but PC40:4 were enriched with smaller differences in species con-
taining AA, but higher increases in DHA containing species. The composition of DHA con-
taining species was slightly different between the CF and the IF with accumulation of DHA in
PCe in the CF. Thus, either endogenously produced DHA is preferably incorporated into PCe
or PCe are preferred when DHA is low abundant to prevent from oxidation. Tracer-studies
might be able to answer this question in future studies.
The phospholipid profile in newborn showed very low level (~50%) of LPC(18:2), PC(32:2),
PC(34:2), PC(36:2) and SM(18:2) in comparison to 4 month old infants. All species presum-
ably contain linoleic acid (18:2) which is the precursor of endogenously synthesised AA. AA
and DHA can be converted from linoleic acid and alpha-linolenic acid (18:3), respectively by
elongation and desaturation of the carbon chain [22]. Phospholipid species containing alpha-
linolenic acid, which are PC(34:3), PC(36:3) and PC(38:3), were also lower (~70%) in newborn
than in infants at 4 month of age, although with smaller deviation. The low abundance of phos-
pholipid species containing 18:2 and 18:3 in newborn indicates a low placental supply, while
AA and DHA were much higher abundant. Since the conversion rate of precursors (18:2 and
18:3) to AA and DHA is low in adults, the rate might be even lower in foetuses and infants
[23]. High demands during late pregnancy for cognitive and visual development is ensured by
the direct placental supply of high level of AA and DHA.
The total amount of PCe was increasing from newborn to 4 month old infants, regardless of
the study group. Regarding to literature, PCe might be important for the healthy neuronal
development and could serve as reservoir for LC-PUFA [24]. Our results showed a dietary
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effect on the PCe content and we speculate about positive long-term effects for cognitive func-
tions. PCe contain high amounts of LC-PUFA and thus the quantity of PCe might be explained
by the consumption of LC-PUFA. The CF did not obtain any additional AA or DHA, while the
IF was supplemented with AA and DHA and breast milk presumably contain highest values of
different LC-PUFA [25]. A suggested preferred incorporation into PCe was not detected. As
shown in Table 3, IF fed infants showed lower percentages of DHA within PCe species than
infants fed CF. Moreover, PCe species without AA or DHA, such as PCe38:0, PCe40:1 or
PCe40:0 were also higher in the group of IF, in comparison to the CF group. Thus, the synthe-
sis of all PCe was promoted by the consumption of the IF. Nevertheless, infants of the BM
group showed the highest values of all PCe species, which emphasized the outstanding role of
breast milk for infants in the context of the suggested healthy properties of PCe.
For an optimal development of infants, breast feeding is assumed to be the best choice of
nutrition during the first 6 months of life. To optimise infant formula fatty acid content, the
analyses of molecular phospholipid species may help to investigate metabolic relations between
nutrition and physiological outcomes. The plasma phospholipid profile of infants fed formula
was separated from the BM infants by PCA. Thus, different diets are represented by the plasma
phospholipid profile. The IF infants showed a phospholipid profile between BM and CF. This
result was confirmed by the group comparison which showed that less species were different
between the IF and BM infants, than between CF and BM. Our results showed that dietary
availability of LC-PUFA has a huge impact on the plasma phospholipids pattern of infants.
Several studies have shown that supplementation of infant formula did improve the LC-PUFA
status in different compartments. Regarding literature of mature breast milk fatty acid compo-
sition of triacylglycerols, the concentration of AA (0.41 +/- 0.05%) is at least twice as high as
DHA (0.18 +/- 0.02%) [25]. In our study, the IF was added by equal amounts (72 mg/ 100 mL)
Table 3. Median values and interquartile ranges (IQR) in % of total arachidonic acid and docosahexaenoic acid species in infant plasma at 4 month
of age. Significant changes between groups are calculated by Mann-Whitney-U tests after Bonferroni correction and marked in gray.
Control formula (n = 79) Intervention formula (n = 83) p-value
Median IQR Median IQR
Arachidonic acid containing species
LPC20:4 1.90% 0.49% 1.99% 0.43% 6.96E-02
PC34:4 0.21% 0.07% 0.24% 0.09% 9.95E-05
PC36:4 51.41% 2.11% 51.55% 2.64% 2.26E-01
PC38:4 35.75% 2.47% 36.20% 2.58% 4.05E-01
PC40:4 1.30% 0.23% 0.94% 0.24% 9.21E-19
PCe34:4 0.05% 0.02% 0.05% 0.02% 2.74E-02
PCe36:4 4.99% 0.87% 4.69% 0.72% 2.13E-03
PCe38:4 3.64% 0.69% 3.53% 0.69% 2.55E-02
PCe40:4 0.61% 0.15% 0.53% 0.13% 7.63E-04
Docosahexaenoic acid containing species
LPC22:6 1.62% 0.49% 1.70% 0.57% 2.49E-02
PC36:6 0.30% 0.16% 0.30% 0.12% 6.47E-01
PC38:6 63.65% 2.57% 66.08% 3.15% 5.88E-14
PC40:6 22.09% 1.72% 22.29% 1.93% 8.92E-01
PCe36:6 0.16% 0.23% 0.15% 0.11% 3.47E-01
PCe38:6 6.70% 1.27% 5.04% 1.22% 9.29E-15
PCe40:6 3.84% 1.10% 2.81% 0.85% 5.33E-16
PCe42:6 1.21% 0.41% 0.81% 0.33% 1.43E-17
doi:10.1371/journal.pone.0162040.t003
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of AA and DHA. Plasma concentrations of phospholipids containing DHA were within the
same region for infants receiving the IF than BM and thus the IF provided appropriate DHA to
match breast milk (Fig 2). However, a concentration of 72 mg/100 mL AA seems not to be
enough, compared to BM infants (Fig 2). To realize a fatty acid composition of infant formulas
most closely to the breastmilk, a higher concentration of AA than 72 mg/ 100 ml should be
considered.
A limitation of the study might be the missing of further interesting lipid fractions, such as
phosphatidylethanolamines, cholesterol ester or triacylglycerols. Since the used method is a
screening method for a serious of phospholipid species, there are limitations in quantification
and identification. Identification occurred based on mass spectrometric detection and in some
cases there might be more than one species behind the mass transition. Identification occurred
to our best knowledge for the highest concentrated species. A further limitation might be the
correction of PCe and SM by internal standard of PC(28:0), which might not compensate for
all class specific effects during sample preparation and ionisation. However, we belief that PC
(28:0) might be suitable for compensating the overwhelming class of effects because of very
similar chemical constitution of PC, PCe and SM. Quantification was applied including isoto-
pomer correction, which can result in higher variation of low concentrated species. Isotopomer
correction was made until M+4 isotopomers to ensure that no false positive results were
obtained.
Conclusion
In conclusion, we have shown that infant plasma phospholipid profile changes from newborn
to 4 month old infants and is dependent on the dietary fatty acid composition. Infants of CF
group, which did not obtain additional LC-PUFA showed values of 40% (AA) and 51% (DHA)
in comparison to newborn. The supplementation of an infant formula with AA and DHA
resulted in markedly increased related phospholipid species. DHA was enriched in PCe of CF
fed infants, probably to save residual DHA from oxidation, while PCe synthesis may be
enhanced by PUFA supply in breast fed and IF infants.
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